Skip to main content
Search
Main content
Three brains with dementia imaged with PET-TSPO

Malpetti Lab

Using specialist brain scans and novel blood tests to measure inflammation and accelerate the development of new treatments

Techniques

Bioinformatics, Flow cytometry, Fluid biomarkers, Human brain imaging

Info

Department of Clinical Neurosciences, University of Cambridge, UK DRI at Cambridge
Dr Maura Malpetti

Accelerating the development of new treatments

Most dementias are degenerative (wear and tear of brain cells) with a build-up of harmful junk proteins and chronic brain inflammation. Higher brain inflammation is linked to more severe symptoms and faster decline over time. Anti-inflammatory or immunity-based treatments might slow or prevent decline. But better tests to measure inflammation are needed to identify who may benefit most from these treatments, when to treat, and importantly which part of the immune system to target. The Malpetti Lab use specialist brain scans and novel blood tests to measure inflammation in volunteers with different dementia types, to accelerate the development of new treatments.

Dr Maura Malpetti

Dr Maura Malpetti is an Emerging Leader at the UK DRI at Cambridge. Find out more about her career and expertise on her profile page.

Maura Malpetti profile

Research summary

Images of TSPO PET as marker of microglial activation in volunteers with Alzheimer’s dementia, frontotemporal dementia and progressive supranuclear palsy.

Images of TSPO PET as marker of microglial activation in volunteers with Alzheimer’s dementia, frontotemporal dementia and progressive supranuclear palsy. Credit: Dr Maura Malpetti

Inflammation in frontotemporal dementia and related disorders: mechanisms, biomarkers and clinical trials

Neuroinflammation is an important pathogenic mechanism in neurodegenerative diseases. However, immunotherapeutic strategies are hampered by lack of knowledge about individual differences in inflammation, their causes and consequences. Dr Malpetti’s studies with PET imaging strongly support the role of central nervous system inflammation in accelerating disease progression in people with Alzheimer’s disease, frontotemporal dementia and primary tauopathies. In people with these conditions, a range of anti-inflammatory treatments could be helpful to slow or prevent decline.

The Malpetti Lab are investigating diverse methods to measure inflammation integrating clinically relevant and mechanistically informative neuroimaging and blood-based markers in people with frontotemporal dementia and primary tauopathies, capturing immune signatures, their interplay with pathology and downstream effects, including synaptic loss and clinical decline. Establishing inflammatory “fingerprints” in people with dementia will facilitate accessible and scalable biomarkers to support personalised medicine, early screening strategies, and target-specific immunomodulatory therapies. To this end, she has established and is leading the 'Open Network for Frontotemporal Dementia Inflammation REsearch' (ON-FIRE). The team applies longitudinal statistical models and multimodal imaging analyses, with an interdisciplinary approach that integrates imaging and clinical data with fluid markers and post-mortem pathology.

Main programme aims:

The Malpetti Lab's overarching aim is to accelerate new treatments for frontotemporal dementia and related disorders. Specifically the team aim to:

  1. Characterise the predictive value of in vivo PET imaging for inflammation, molecular pathology and synaptic loss in frototemporal dementia, Alzheimer’s disease and related conditions
  2. Identify novel clinically viable and mechanistically relevant PET and fluid-based biomarkers in dementias to empower target discovery and clinical trials
  3. Investigate brain and immune changes in pre-symptomatic genetic frontotemporal dementia for early interventions

Vacancies

Post-Doctoral Research Associate / Research Assistant (Fixed Term)
Location
UK DRI at Cambridge
Deadline
08 Dec, 2024
Post-Doctoral Research Associate (Fixed Term)
Location
UK DRI at Cambridge
Deadline
08 Dec, 2024

Key publications

Brain
Published

Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.

Authors
Maura Malpetti, Rogier A Kievit, Luca Passamonti, P Simon Jones, Kamen A Tsvetanov, Timothy Rittman, Elijah Mak, Nicolas Nicastro, W Richard Bevan-Jones, Li Su, Young T Hong, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Rowe
Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
Brain
Published

Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia.

Authors
Maura Malpetti, Thomas E Cope, Duncan Street, P Simon Jones, Frank H Hezemans, Elijah Mak, Kamen A Tsvetanov, Timothy Rittman, W Richard Bevan-Jones, Karalyn Patterson, Luca Passamonti, Tim D Fryer, Young T Hong, Franklin I Aigbirhio, John T O'Brien, James B Rowe
Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia.
J Neurol Neurosurg Psychiatry
Published

Neuroinflammation predicts disease progression in progressive supranuclear palsy.

Authors
Maura Malpetti, Luca Passamonti, Peter Simon Jones, Duncan Street, Timothy Rittman, Timothy D Fryer, Young T Hong, Patricia Vàsquez Rodriguez, William Richard Bevan-Jones, Franklin I Aigbirhio, John Tiernan O'Brien, James Benedict Rowe
Neuroinflammation predicts disease progression in progressive supranuclear palsy.
Ann Neurol
Published

Synaptic Loss in Frontotemporal Dementia Revealed by [11 C]UCB-J Positron Emission Tomography.

Authors
Maura Malpetti, P Simon Jones, Thomas E Cope, Negin Holland, Michelle Naessens, Matthew A Rouse, Timothy Rittman, George Savulich, David J Whiteside, Duncan Street, Tim D Fryer, Young T Hong, Selena Milicevic Sephton, Franklin I Aigbirhio, John T O Brien, James B Rowe
Synaptic Loss in Frontotemporal Dementia Revealed by [11 C]UCB-J Positron Emission Tomography.

Lab members

Collaborators

Lab funders

Thank you to all those who support the Malpetti Lab!